You are here: Home » Reuters » News
Business Standard

U.S. FDA approves expanded use of AstraZeneca cancer drug

Reuters 

By Toni Clarke(Reuters) - The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.The drug belongs to a class of drug known as PARP inhibitors that has already been used to treat advanced BRCA-mutated ovarian cancer, the FDA said.This is the first time a PARP inhibitor has been approved to treat breast cancer and the first time any drug has been approved to treat certain patients with metastatic breast cancer ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Fri, January 12 2018. 22:56 IST
RECOMMENDED FOR YOU